Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial

Inclusion Criteria: * Male or female≥ 18 years of age * Cirrhosis related to hepatitis C or hepatitis B virus without viral replication for at least 2 years. Or Cirrhosis related to alcohol consumption (active or abstinent) Or Cirrhosis related to metabolic syndrome or cryptogenic with BMI \< 30 kg/m2 * 2 TE-LSM (Fibroscan®) performed in fasting conditions, using either the M or the XL probe \>=25 kPa, within 12 months before inclusion * Absence of medium or large varices or small varices with red signs at endoscopy within 3 months before inclusion * Child-Pugh A5 to B8 * Affiliation to a French social security system. * Written informed consent obtained from the participant or participant's legal representative * For child-bearing aged women, contraception using oral contraceptive, or intrauterine device or mechanical contraception Exclusion Criteria: * History of overt ascites or encephalopathy \<12 months before inclusion * Treatment with either diuretics or lactulose or rifaximin \<3 months before inclusion * Any history of portal hypertension related bleeding * Baseline heart rate \<65/min or systolic blood pressure \<100 mm Hg * Previous transjugular intrahepatic portosystemic shunt (TIPSS) or liver transplantation * Previous history or active hepatocellular carcinoma * Glomerular filtration rate (CKD-Epi) \< 30 mL/min * Strict indication to selective or nonselective beta-blockers: history of acute myocardial infarction, congestive heart failure * Strict contraindi…